Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
42 Cards in this Set
- Front
- Back
Epinephrine
|
alpha & beta Adrenergic agonist
MOA: beta-2 agonist --> increased cAMP -->immediate relaxation of bronchial smooth muscle cells-->bronchodilation |
|
Albuterol/Ventolin, Proventil
Salmeterol/Serevent |
beta-2 agonist
(Salmeterol long acting beta-2 agonist) MOA: Bronchodilation via --> beta-2-adrenergic receptor stimulation-->increased cAMP levels-->bronchial smooth muscle relaxation |
|
Beclomethasone/beclovent
|
corticosteroid
MOA: decreased inflammation & edema in respiratory tract via reduction in # & activity of møs, eos, t-lymphs, decreased permeability of capillaries, inhibited release of leukotrienes |
|
Cromolyn/Intal
|
mast cell inhibitor
MOA: prevents release of inflammatory mediators (histamine) from mast cells, møs, neuts, eos |
|
Zafirlukast/Accolate
|
Leukotriene receptor antagonist
MOA: competitive antagonism of leukotriene D4 & E4 receptors--> inhibits bronchoconstriction |
|
Prednisone/Deltasone
|
corticosteroid
MOA: decrease inflammation & edema in respiratory tract |
|
Diphenyhydramine/Benadryl
|
sedating antihistamine
MOA: H1 receptor blocker the production and release of histamine is not blocked! |
|
Loratadine/Claritin
|
non-sedating antihistimine
MOA: H1 receptor antagonist |
|
Codeine
|
antitussive, narcotic analgesic and cough suppressant
MOA: suppresses the sensitivity of CNS cough centers |
|
Dextromethorphan
|
antitussive, synthetic derivative of codeine analog
MOA: suppresses the sensitivity of CNS cough centers |
|
Morphine sulfate/MS Contin
|
narcotic analgesic
MOA: opiod agonist, raise pain threshold at spinal cord level, alter brain's perception of pain |
|
Fentanyl/Duragesic
|
narcotic analgesic
MOA: similar to morphine w/80x the analgesic property of morphine |
|
Codeine
|
analgesic
MOA: opiod agonist, weaker than morphine |
|
Naloxone/Narcan
|
narcotic antagonist
MOA: bind with high affinity to opiod receptors but fail to activate the receptor mediated response |
|
Aspirin
|
NSAID analgesic
MOA: irreversible inhibition of COX-1 & COX-2 enzymes. anti-inflamm & analgesic effects dt blockade of prostaglandin synthesis at target tissues. anti-pyretic effect dt blockade at thermoregulatory centers in HTH. PGE2 sensitizes nerve endings to actions of bradykinins, histamines & other inflammatory mediators |
|
Ibuprofen/Motrin, Advil
|
NSAID analgesic
MOA: reversible inhibition of COX-1 & COX-2 enzymes effect dt blockade of prostaglandin synthesis at target tissue |
|
Celecoxib/Celebrex
|
NSAID analgesic
MOA: reversible selective COX-2 inhibition |
|
Acetaminophen/Tylenol
|
analgesic, antipyretic
MOA: weak peripheral blockade of prostaglandin synthesis |
|
Lidocaine/Xylocaine
|
amide local anesthetic
MOA: temporary reduciton of nerve membrane permeability to Na+ action potentials cannot be generated or propagated |
|
Benzonatate/Tessalon
|
ester local anesthetic
MOA: numbing of stretch receptors in the bronchus diminishes cough reflex |
|
Phenobarbitol
|
sedative hypnotic/barbituate
MOA: binding to barbituate receptors in the CNS-->interruption of Na/K ion exchange = enhanced GABA sensitivity |
|
Diazepam/Valium
|
anxiolytic/benzodiazepine/sedative hypnotic
MOA: GABA agonist. binds to benzodiazepine receptor--> enhancing GABA activity |
|
Flumazenil
|
benzodiazepine receptor antagonist
MOA: competitive antagonist |
|
Imipramine/Tofranil
|
antidepressant
MOA: blocks reuptake of norepinephrine and seratonin |
|
Bupropion/Wellbutrin, Zyban
|
atypical antidepressant
MOA: inhibits reuptake of norepi, seratonin, and at high doses, dopamine |
|
Isocarboxazid/Marplan
|
MOAI antidepressant
MOA: inhibits monoamine oxidase |
|
Fluoxetine/Prozac
|
MOA: SSRI antidepressant
|
|
Lithium
|
antidepressant
MOA: inhibits synthesis of the second messenger IP3 |
|
Methylphenidate/Ritalin, Concerta
|
CNS stimulant
MOA: indirect acting adrenergic agonist increases release of norepi |
|
Levodopa/L-Dopa
|
Antiparkinsonian
MOA: increases synthesis of dopamine |
|
Bromocriptine/Parlodel
|
Antiparkinsonian
MOA: dopamine receptor agonist |
|
Selegiline/Eldepryl
|
Antiparkinsonian
MOA: MAO inhibitor |
|
Benztropine/Congentin
|
Antiparkinsonian
MOA: muscarinic & histaminic receptor antagonist anti-cholinergic |
|
Amantadine/Symmetrel
|
Antiparkinsonian
MOA: increased release of dopamine by unknown mechanism |
|
Entacapone/Comtan
|
Antiparkinsonian
MOA: COMT inhibitor |
|
Donepezil/Aricept
|
Alzheimers
MOA: Acetylcholinesterase inhibitor |
|
Interferon beta-1b/Betaseron
|
multiple sclerosis
MOA: immune modulation/biologic response modifier |
|
Clonazepam/Klonapin
|
benzodiazepine
MOA: anti-seizure MOA unclear |
|
Phenytoin/Dilantin
|
anticonvulsant
MOA: reduces Na+, Ca+, and K currents across neuronal membranes. unclear as to which effect is responsible for seizure prophylaxis |
|
Primidone/Mysoline
|
anticonvulsant
MOA: exact MOA unknown, but phenobarbitol is a metabolite of primidone |
|
Carbamazepine/Tegretol
|
anticonvulsant
MOA: similar to phenytoin in the reduction of Na+, Ca+ & K currents across neuronal membranes |
|
Valproic acid/Depakote
|
anticonvulsant
MOA: unknown, enhancement of GABA transmission has been postulated |